Status:
COMPLETED
HD12 for Advanced Stages
Lead Sponsor:
University of Cologne
Conditions:
Hodgkin´s Lymphoma
Eligibility:
All Genders
16-65 years
Phase:
PHASE3
Brief Summary
This study is designed to test (1) whether the BEACOPP dosage can be reduced to baseline in the last 4 cycles without loss of effectiveness, and (2) whether consolidating irradiation is necessary foll...
Eligibility Criteria
Inclusion
- Hodgkin´s lymphoma (histologically proven)
- CS(PS) IIB with one or both of the risk factors:
- bulky mediastinal mass (\> 1/3 of maximum transverse thorax diameter)
- extranodal involvement
- CS(PS) III, IV
- written informaed consent
Exclusion
- Leukocytes \<3000/microl
- Platelets \<100000/microl
- Hodgkin´s Disease as "composite lymphoma"
- Activity index (WHO) \< grade 2
Key Trial Info
Start Date :
January 1 1999
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00265031
Start Date
January 1 1999
Last Update
June 25 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.